Published in J Mol Biol on December 28, 2009
Global analysis of protein N-myristoylation and exploration of N-myristoyltransferase as a drug target in the neglected human pathogen Leishmania donovani. Chem Biol (2015) 1.47
Targeting protein lipidation in disease. Trends Mol Med (2012) 1.37
Selective inhibitors of protozoan protein N-myristoyltransferases as starting points for tropical disease medicinal chemistry programs. PLoS Negl Trop Dis (2012) 1.36
A fluorescence-based assay for N-myristoyltransferase activity. Anal Biochem (2011) 1.20
Global profiling of co- and post-translationally N-myristoylated proteomes in human cells. Nat Commun (2014) 1.19
A tetracycline-repressible transactivator system to study essential genes in malaria parasites. Cell Host Microbe (2012) 1.16
Discovery of Plasmodium vivax N-myristoyltransferase inhibitors: screening, synthesis, and structural characterization of their binding mode. J Med Chem (2012) 1.09
Design and synthesis of inhibitors of Plasmodium falciparum N-myristoyltransferase, a promising target for antimalarial drug discovery. J Med Chem (2012) 1.03
Recent Developments in Drug Discovery for Leishmaniasis and Human African Trypanosomiasis. Chem Rev (2014) 1.00
Structure-based design of potent and selective Leishmania N-myristoyltransferase inhibitors. J Med Chem (2014) 0.95
Design and synthesis of high affinity inhibitors of Plasmodium falciparum and Plasmodium vivax N-myristoyltransferases directed by ligand efficiency dependent lipophilicity (LELP). J Med Chem (2014) 0.95
Functional analysis of Leishmania cyclopropane fatty acid synthetase. PLoS One (2012) 0.91
Diverse modes of binding in structures of Leishmania major N-myristoyltransferase with selective inhibitors. IUCrJ (2014) 0.90
Acylation in trypanosomatids: an essential process and potential drug target. Trends Parasitol (2014) 0.88
Trafficking and release of Leishmania metacyclic HASPB on macrophage invasion. Cell Microbiol (2012) 0.88
A target repurposing approach identifies N-myristoyltransferase as a new candidate drug target in filarial nematodes. PLoS Negl Trop Dis (2014) 0.84
Fatty acylation of proteins: The long and the short of it. Prog Lipid Res (2016) 0.81
The Leishmania major BBSome subunit BBS1 is essential for parasite virulence in the mammalian host. Mol Microbiol (2013) 0.81
Global Profiling and Inhibition of Protein Lipidation in Vector and Host Stages of the Sleeping Sickness Parasite Trypanosoma brucei. ACS Infect Dis (2016) 0.77
Structure and Functional Diversity of GCN5-Related N-Acetyltransferases (GNAT). Int J Mol Sci (2016) 0.77
A new, robust, and nonradioactive approach for exploring N-myristoylation. J Lipid Res (2012) 0.77
N-terminal region of the catalytic domain of human N-myristoyltransferase 1 acts as an inhibitory module. PLoS One (2015) 0.77
Association of NMT2 with the acyl-CoA carrier ACBD6 protects the N-myristoyltransferase reaction from palmitoyl-CoA. J Lipid Res (2015) 0.76
Discovery of high affinity inhibitors of Leishmania donovani N-myristoyltransferase. Medchemcomm (2015) 0.76
A Multiplatform Metabolomic Approach to the Basis of Antimonial Action and Resistance in Leishmania infantum. PLoS One (2015) 0.76
N-myristoyltransferase in the leukocytic development processes. Cell Tissue Res (2011) 0.76
Validation of N-myristoyltransferase as Potential Chemotherapeutic Target in Mammal-Dwelling Stages of Trypanosoma cruzi. PLoS Negl Trop Dis (2016) 0.75
Synthetic oxoisoaporphine alkaloids: in vitro, in vivo and in silico assessment of antileishmanial activities. PLoS One (2013) 0.75
Ursolic Acid, a Natural Pentacylcic Triterpene from Ochrosia elliptica and Its Role in The Management of Certain Neglected Tropical Diseases. Pharmacogn Mag (2016) 0.75
Structure-guided optimization of quinoline inhibitors of Plasmodium N-myristoyltransferase. Medchemcomm (2016) 0.75
Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr (2004) 227.01
The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr (1994) 187.88
Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr (1997) 137.43
Protein production by auto-induction in high density shaking cultures. Protein Expr Purif (2005) 29.74
ESPript: analysis of multiple sequence alignments in PostScript. Bioinformatics (1999) 21.85
Developments in the CCP4 molecular-graphics project. Acta Crystallogr D Biol Crystallogr (2004) 13.53
Recent improvements to the PROSITE database. Nucleic Acids Res (2004) 11.89
An approach to multi-copy search in molecular replacement. Acta Crystallogr D Biol Crystallogr (2000) 7.78
Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol (2007) 7.36
Drug resistance in leishmaniasis. Clin Microbiol Rev (2006) 7.35
Fatty acylation of proteins: new insights into membrane targeting of myristoylated and palmitoylated proteins. Biochim Biophys Acta (1999) 6.98
Comparative genomic analysis of three Leishmania species that cause diverse human disease. Nat Genet (2007) 4.58
Enhanced human cell engraftment in mice deficient in RAG2 and the common cytokine receptor gamma chain. Br J Haematol (1998) 2.97
ARP/wARP and molecular replacement: the next generation. Acta Crystallogr D Biol Crystallogr (2007) 2.43
Genetic and biochemical studies of protein N-myristoylation. Annu Rev Biochem (1994) 2.30
N-terminal N-myristoylation of proteins: prediction of substrate proteins from amino acid sequence. J Mol Biol (2002) 2.18
Myristoyl-CoA:protein N-myristoyltransferase, an essential enzyme and potential drug target in kinetoplastid parasites. J Biol Chem (2002) 2.08
Current scenario of drug development for leishmaniasis. Indian J Med Res (2006) 2.06
Disruption of the yeast N-myristoyl transferase gene causes recessive lethality. Science (1989) 1.83
Acylation-dependent protein export in Leishmania. J Biol Chem (2000) 1.77
Molecules incorporating a benzothiazole core scaffold inhibit the N-myristoyltransferase of Plasmodium falciparum. Biochem J (2007) 1.75
Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses. Nat Med (2003) 1.75
Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J Immunol (2000) 1.72
Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics. Mol Biochem Parasitol (2003) 1.61
Kinetic and structural evidence for a sequential ordered Bi Bi mechanism of catalysis by Saccharomyces cerevisiae myristoyl-CoA:protein N-myristoyltransferase. J Biol Chem (1991) 1.34
Characterization and selective inhibition of myristoyl-CoA:protein N-myristoyltransferase from Trypanosoma brucei and Leishmania major. Biochem J (2006) 1.30
Crystal structure of the anti-fungal target N-myristoyl transferase. Nat Struct Biol (1998) 1.29
Myristoyl-CoA:protein N-myristoyltransferase depletion in trypanosomes causes avirulence and endocytic defects. Mol Biochem Parasitol (2009) 1.28
Structure of N-myristoyltransferase with bound myristoylCoA and peptide substrate analogs. Nat Struct Biol (1998) 1.27
The leishmaniases--survival and expansion in a changing world. A mini-review. Mem Inst Oswaldo Cruz (2007) 1.22
Kinetoplastid PPEF phosphatases: dual acylated proteins expressed in the endomembrane system of Leishmania. Mol Biochem Parasitol (2006) 1.21
4-oxatetradecanoic acid is fungicidal for Cryptococcus neoformans and inhibits replication of human immunodeficiency virus I. J Biol Chem (1992) 1.20
Structures of Saccharomyces cerevisiae N-myristoyltransferase with bound myristoylCoA and peptide provide insights about substrate recognition and catalysis. Biochemistry (2001) 1.15
Genetic and biochemical studies establish that the fungicidal effect of a fully depeptidized inhibitor of Cryptococcus neoformans myristoyl-CoA:protein N-myristoyltransferase (Nmt) is Nmt-dependent. J Biol Chem (1998) 1.12
Comparison of myristoyl-CoA:protein N-myristoyltransferases from three pathogenic fungi: Cryptococcus neoformans, Histoplasma capsulatum, and Candida albicans. J Biol Chem (1994) 1.11
The structure of myristoyl-CoA:protein N-myristoyltransferase. Biochim Biophys Acta (1999) 1.08
Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis. Vaccine (2007) 1.06
Synthesis and biological activities of benzofuran antifungal agents targeting fungal N-myristoyltransferase. Bioorg Med Chem (2003) 1.03
Comparison of the acyl chain specificities of human myristoyl-CoA synthetase and human myristoyl-CoA:protein N-myristoyltransferase. J Biol Chem (1993) 1.01
N-myristoylation of Arf proteins in Candida albicans: an in vivo assay for evaluating antifungal inhibitors of myristoyl-CoA: protein N-myristoyltransferase. Microbiology (1997) 1.00
Crystal structures of Candida albicans N-myristoyltransferase with two distinct inhibitors. Chem Biol (2002) 0.98
Isothermal titration calorimetric studies of Saccharomyces cerevisiae myristoyl-CoA:protein N-myristoyltransferase. Determinants of binding energy and catalytic discrimination among acyl-CoA and peptide ligands. J Biol Chem (1994) 0.90
Scanning alanine mutagenesis and de-peptidization of a Candida albicans myristoyl-CoA:protein N-myristoyltransferase octapeptide substrate reveals three elements critical for molecular recognition. J Biol Chem (1997) 0.90
Pre-steady-state kinetic studies of Saccharomyces cerevisiae myristoylCoA:protein N-myristoyltransferase mutants identify residues involved in catalysis. Biochemistry (2001) 0.87
Immunocytochemical characterization and subcellular localization of human myristoyl-CoA: protein N-myristoyltransferase in HeLa cells. Exp Cell Res (1996) 0.85
FTR1335 is a novel synthetic inhibitor of Candida albicans N-myristoyltransferase with fungicidal activity. Biol Pharm Bull (2005) 0.83
The genome of the kinetoplastid parasite, Leishmania major. Science (2005) 8.64
Comparative genomic analysis of three Leishmania species that cause diverse human disease. Nat Genet (2007) 4.58
Condition-dependent transcriptome reveals high-level regulatory architecture in Bacillus subtilis. Science (2012) 4.41
TriTrypDB: a functional genomic resource for the Trypanosomatidae. Nucleic Acids Res (2009) 3.79
N-myristoyltransferase inhibitors as new leads to treat sleeping sickness. Nature (2010) 2.90
How insulin engages its primary binding site on the insulin receptor. Nature (2013) 2.52
Global network reorganization during dynamic adaptations of Bacillus subtilis metabolism. Science (2012) 2.38
Conserved arginine residues implicated in ATP hydrolysis, nucleotide-sensing, and inter-subunit interactions in AAA and AAA+ ATPases. J Struct Biol (2004) 2.15
Myristoyl-CoA:protein N-myristoyltransferase, an essential enzyme and potential drug target in kinetoplastid parasites. J Biol Chem (2002) 2.08
Chromosome and gene copy number variation allow major structural change between species and strains of Leishmania. Genome Res (2011) 1.90
GeneDB--an annotation database for pathogens. Nucleic Acids Res (2011) 1.82
Molecules incorporating a benzothiazole core scaffold inhibit the N-myristoyltransferase of Plasmodium falciparum. Biochem J (2007) 1.75
Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses. Nat Med (2003) 1.75
Toll-like receptor 4 contributes to efficient control of infection with the protozoan parasite Leishmania major. Infect Immun (2004) 1.65
The immunopathology of experimental visceral leishmaniasis. Immunol Rev (2004) 1.64
Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics. Mol Biochem Parasitol (2003) 1.61
Stromal cells direct local differentiation of regulatory dendritic cells. Immunity (2004) 1.58
Protein myristoylation in health and disease. J Chem Biol (2009) 1.57
The structure of CodY, a GTP- and isoleucine-responsive regulator of stationary phase and virulence in gram-positive bacteria. J Biol Chem (2006) 1.54
Ether phospholipids and glycosylinositolphospholipids are not required for amastigote virulence or for inhibition of macrophage activation by Leishmania major. J Biol Chem (2003) 1.52
Sphingolipid-free Leishmania are defective in membrane trafficking, differentiation and infectivity. Mol Microbiol (2004) 1.45
Distinct roles for IL-6 and IL-12p40 in mediating protection against Leishmania donovani and the expansion of IL-10+ CD4+ T cells. Eur J Immunol (2006) 1.44
Lipid spirals in Bacillus subtilis and their role in cell division. Mol Microbiol (2008) 1.40
Crystal structure of dihydrodipicolinate synthase (BA3935) from Bacillus anthracis at 1.94 A resolution. Proteins (2006) 1.40
The protozoan inositol phosphorylceramide synthase: a novel drug target that defines a new class of sphingolipid synthase. J Biol Chem (2006) 1.39
Crystal structure of foot-and-mouth disease virus 3C protease. New insights into catalytic mechanism and cleavage specificity. J Biol Chem (2005) 1.38
Selective inhibitors of protozoan protein N-myristoyltransferases as starting points for tropical disease medicinal chemistry programs. PLoS Negl Trop Dis (2012) 1.36
Apoptosis in hypoxic human pancreatic islets correlates with HIF-1alpha expression. FASEB J (2002) 1.36
Interaction of transcriptional intermediary factor 2 nuclear receptor box peptides with the coactivator binding site of estrogen receptor alpha. J Biol Chem (2002) 1.35
Protein engineering 20 years on. Nat Rev Mol Cell Biol (2002) 1.34
N-myristoyltransferase: a prospective drug target for protozoan parasites. ChemMedChem (2008) 1.33
Dynamic imaging of experimental Leishmania donovani-induced hepatic granulomas detects Kupffer cell-restricted antigen presentation to antigen-specific CD8 T cells. PLoS Pathog (2010) 1.32
Functional analysis of TbARL1, an N-myristoylated Golgi protein essential for viability in bloodstream trypanosomes. J Cell Sci (2005) 1.30
Randomized clinical trial of 3 types of physical exercise for patients with Parkinson disease. JAMA Neurol (2013) 1.30
Characterization and selective inhibition of myristoyl-CoA:protein N-myristoyltransferase from Trypanosoma brucei and Leishmania major. Biochem J (2006) 1.30
The crystal structure of YloQ, a circularly permuted GTPase essential for Bacillus subtilis viability. J Mol Biol (2004) 1.29
Myristoyl-CoA:protein N-myristoyltransferase depletion in trypanosomes causes avirulence and endocytic defects. Mol Biochem Parasitol (2009) 1.28
Dimer formation and transcription activation in the sporulation response regulator Spo0A. J Mol Biol (2002) 1.27
Trypanosoma brucei ARF1 plays a central role in endocytosis and golgi-lysosome trafficking. Mol Biol Cell (2006) 1.26
Site-specific N-terminal labelling of proteins in vitro and in vivo using N-myristoyl transferase and bioorthogonal ligation chemistry. Chem Commun (Camb) (2007) 1.25
Chemical and biomimetic total syntheses of natural and engineered MCoTI cyclotides. Org Biomol Chem (2008) 1.24
The crystal structure of the AAA domain of the ATP-dependent protease FtsH of Escherichia coli at 1.5 A resolution. Structure (2002) 1.22
Kinetoplastid PPEF phosphatases: dual acylated proteins expressed in the endomembrane system of Leishmania. Mol Biochem Parasitol (2006) 1.21
N-Myristoyl transferase-mediated protein labelling in vivo. Org Biomol Chem (2008) 1.21
A fluorescence-based assay for N-myristoyltransferase activity. Anal Biochem (2011) 1.20
The structure of the oligopeptide-binding protein, AppA, from Bacillus subtilis in complex with a nonapeptide. J Mol Biol (2005) 1.19
Loss of dendritic cell migration and impaired resistance to Leishmania donovani infection in mice deficient in CCL19 and CCL21. J Immunol (2006) 1.19
Activity-based probes: discovering new biology and new drug targets. Chem Soc Rev (2010) 1.18
Gankyrin: a new oncoprotein and regulator of pRb and p53. Trends Cell Biol (2006) 1.17
Multifunctional protein labeling via enzymatic N-terminal tagging and elaboration by click chemistry. Nat Protoc (2011) 1.17
Division site recognition in Escherichia coli and Bacillus subtilis. FEMS Microbiol Rev (2007) 1.16
An ATP-binding cassette-type cysteine transporter in Campylobacter jejuni inferred from the structure of an extracytoplasmic solute receptor protein. Mol Microbiol (2005) 1.16
Structural and biochemical characterization of a mitochondrial peroxiredoxin from Plasmodium falciparum. Mol Microbiol (2006) 1.14
pBaSysBioII: an integrative plasmid generating gfp transcriptional fusions for high-throughput analysis of gene expression in Bacillus subtilis. Microbiology (2010) 1.14
The crystal structure of gankyrin, an oncoprotein found in complexes with cyclin-dependent kinase 4, a 19 S proteasomal ATPase regulator, and the tumor suppressors Rb and p53. J Biol Chem (2003) 1.14
The p53 pathway promotes efficient mitochondrial DNA base excision repair in colorectal cancer cells. Cancer Res (2006) 1.14
Comparative expression profiling of Leishmania: modulation in gene expression between species and in different host genetic backgrounds. PLoS Negl Trop Dis (2009) 1.14
The stage-regulated HASPB and SHERP proteins are essential for differentiation of the protozoan parasite Leishmania major in its sand fly vector, Phlebotomus papatasi. Cell Microbiol (2010) 1.13
Bioorthogonal chemical tagging of protein cholesterylation in living cells. Chem Commun (Camb) (2011) 1.13
The crystal structures of human S100A12 in apo form and in complex with zinc: new insights into S100A12 oligomerisation. J Mol Biol (2009) 1.12
The interaction of RNA with TRAP: the role of triplet repeats and separating spacer nucleotides. J Mol Biol (2004) 1.11
Conservation of structure and mechanism in primary and secondary transporters exemplified by SiaP, a sialic acid binding virulence factor from Haemophilus influenzae. J Biol Chem (2006) 1.11
Insulin and insulin-like growth factor II differentially regulate endocytic sorting and stability of insulin receptor isoform A. J Biol Chem (2012) 1.09
Discovery of Plasmodium vivax N-myristoyltransferase inhibitors: screening, synthesis, and structural characterization of their binding mode. J Med Chem (2012) 1.09
Insights into cleavage specificity from the crystal structure of foot-and-mouth disease virus 3C protease complexed with a peptide substrate. J Mol Biol (2009) 1.06
RepSeq--a database of amino acid repeats present in lower eukaryotic pathogens. BMC Bioinformatics (2007) 1.06
Potent inhibitors of beta-tryptase and human leukocyte elastase based on the MCoTI-II scaffold. J Med Chem (2009) 1.06
Higher-throughput approaches to crystallization and crystal structure determination. Biochem Soc Trans (2008) 1.06
Structural and mutagenic analysis of foot-and-mouth disease virus 3C protease reveals the role of the beta-ribbon in proteolysis. J Virol (2006) 1.06
Structural basis of the sulphate starvation response in E. coli: crystal structure and mutational analysis of the cofactor-binding domain of the Cbl transcriptional regulator. J Mol Biol (2006) 1.05